mHealthcare is a data-centric biotech research company focused on the very-early detection of infant neurodivergent strengths and challenges. We leverage AI, machine learning, and non-linear algorithms to translate neurological insights into the early detection of developmental differences. We are launching multiple ground-breaking technologies to transform infant neurodiagnostics screenings, starting with autism. Our proprietary technology calculates a standardized risk trajectory of a newborn developing autism with 95% efficacy!

mHealthcare is innovating clinical neuropsychology. Our SaaS infant neurodivergent screenings technologies unlock hidden gems about the human brain, starting from birth!

- Michael E. Johnson, CEO

Disrupting Neuroscience Paradigms

Our HIPAA-compliant SaaS cloud analyzes biodata providing new understandings about infant human brain function. By leveraging proprietary annual brain mapping EMRs and predictive analytics, mHealthcare will create an entirely new industry, “Infant Cognitive Behavioral Therapeutics,” unlocking invaluable early-intervention insights to impact neurodivergent obstacles.